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Standard of care for cancer screening: the term implies certainty and consensus. Physicians, 
patients, and organizations have created guidelines, policies and regulations regarding how, 
when, and for whom screening should be used or reimbursed; cumulatively, these actions 
become the standards of care. However, these standards vary markedly across organ type, 
often without rationale or evidence.
In principle, standards of care should originate from common systematic methods and goals 
and create consistent, evidence-based recommendations for screening methods, 
implementation and desired outcomes. However, current practices are guided by sometimes 
conflicting clinical studies, professional society opinions, independent panels, advocacy 
groups, legislative mandates and payer regulations.1,2
In this Viewpoint, we highlight three areas in which cancer screening standards differ 
markedly for breast, colorectal, and cervical cancer: funding, quality measures, and 
reporting. These variations were delineated through a cross-disciplinary collaboration among 
scientists, healthcare organizations, and society leaders within the National Cancer 
Institute’s Population-Based Research Optimizing Screening through Personalized 
Regimens (PROSPR) consortium.3 PROSPR studies how breast, cervical and colorectal 
cancer screening is implemented in diverse, real-world settings in the United States. We 
illustrate the absence of a cohesive approach to cancer screening, suggest key questions to 
address, and outline a framework for creating true “standards of care” to provide more 
consistent, effective and patient-centered cancer screening.
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 FUNDING OF CANCER SCREENING AND FOLLOW-UP
 Federal/State Programs
Federal and state funding varies substantially by organ type (Table-online). Congressional 
legislation, through the Breast and Cervical Cancer Mortality Prevention Act of 1990, 
directed the Centers for Disease Control and Prevention (CDC) to create the National Breast 
and Cervical Cancer Early Detection Program. This program provides free breast and 
cervical cancer screening and diagnostic services to women ages 21-64 years at ≤250% of 
federal poverty levels. In 2000, Congress added the Breast and Cervical Cancer Prevention 
and Treatment Act to provide program members with detected cancers treatment through 
Medicaid coverage, an option ultimately implemented in all 50 states.1
For colorectal cancer, a leading cause of cancer deaths, the CDC’s Colorectal Cancer 
Control Program is structured much differently.2 First, this program was funded in 2009, 
almost 19 years after the breast cancer legislation and 13 years after the US Preventive 
Services Task Force (USPSTF) recommended colorectal cancer screening. Second, it 
predominantly provides education and outreach rather than screening services. Third, it does 
not provide treatment for detected cancers. Fourth, it currently covers only 25 states plus 
four tribal organizations.
Reflecting these differences, the National Breast and Cervical Cancer Early Detection 
Program supported 331,313 breast and 208,682 cervical cancer screening exams in 2013.1 In 
comparison, the Colorectal Cancer Control Program directly supported only 13,425 
colorectal cancer screening exams in 2014, even though colorectal cancer affects both men 
and women.2
 Medicare
Among Medicare beneficiaries, cancer screening coverage varies by organ and test results. 
Medicare started coverage for mammography in 1991, for cervical cytology in 1990,4 for 
fecal blood testing in 1998 and for colonoscopy in 2001. For screening procedures already 
approved by Medicare, the 2010 Affordable Care Act (ACA) requires coverage without 
patient cost-sharing (e.g., co-pays, deductible charges) of preventive services recommended 
by the USPSTF. However, unlike private insurance companies, the ACA allows Medicare 
discretion regarding whether to cover new preventive services, even if recommended by the 
USPSTF. This recently resulted in controversy regarding whether the USPSTF’s new 
recommendation for lung cancer screening for some smokers, with computerized 
tomography, might not be covered by Medicare.
However, for all these cancers, coverage “loopholes” exist for diagnostic services. For 
example, if a screening colonoscopy removes a polyp, it is converted to a “diagnostic” exam, 
subject to cost-sharing.5 Similar unexpected fees may occur for colonoscopies performed 
after positive fecal blood tests, and for evaluations performed after abnormal breast or 
cervical cancer screening tests, even if the follow-up exams are normal.5
Corley et al. Page 2
JAMA. Author manuscript; available in PMC 2016 June 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
 Medicaid
Medicaid coverage includes cancer screening through the National Breast and Cervical 
Cancer Early Detection Program for eligible individuals. Medicaid also authorizes colorectal 
cancer screening; however, unlike Medicare, there is no uniform coverage for any cancer 
type. Medicaid reimbursement varies between states and even within states.
Similar to Medicare, Medicaid coverage differences also extend to the follow-up and 
treatment of positive screening tests across all three cancer types, though these vary by state. 
In California, for example, patients with breast or cervical cancer are eligible for no-cost 
treatment through Medicaid, if not eligible by federal requirements, even though coverage is 
not available for other life-threatening conditions, including colorectal cancer.
 Private and self-insured plans
The ACA also requires private plans to cover recommended breast, cervical, and colorectal 
cancer screening tests without co-payments. However, controversy surrounding the 2009 
USPSTF recommendations regarding starting biennial mammography at age 50 led to the 
ACA covering mammography at an earlier starting age and more frequently than USPSTF 
recommendations, whereas no such USPSTF recommendation exceptions exist for cervical 
or colorectal cancer screening. State laws regarding cancer screening also vary by cancer; 
for example, all states except Utah require private insurance coverage of screening 
mammograms though, similar to Medicare, for all organ types, plans may require cost-
sharing of procedures classified as “diagnostic”.
 QUALITY MEASURES FOR TEST PERFORMANCE AND FOLLOW-UP
Screening test quality and follow-up standards vary widely across organs. Many 
mammography standards are federally mandated. In 1992, the Mammography Quality 
Standards Act tasked the Food and Drug Administration (FDA) with developing regulations 
for mammography performance, facility inspections, and other factors. For breast and 
cervical cancer screening, the National Breast and Cervical Cancer Early Detection Program 
established benchmarks for timely care (e.g., diagnostic testing <60 days after abnormal 
screening and treatment <60 days after cancer diagnoses). For colorectal cancer screening, 
no uniform quality measures for performance or standards for timely follow-up exist and 
practices vary.6 Thus, at one extreme, the mandated prompt follow-up of abnormal 
mammograms attains uniform methods and rapid test completion, but with modest evidence 
regarding patient outcomes from these resource-intensive efforts. At the other extreme, few 
quality standards exist for testing or follow-up of positive fecal or cervical tests, despite 
outcome data regarding possible harms from delayed follow-up.
 REPORTING OF SCREENING TEST RESULTS
Reporting standards for screening test results also vary widely by organ. The Mammography 
Quality Standards Act requires facilities to notify patients and providers of normal results 
within 30 days. Some abnormal results require provider communications within 3 days and 
patient notification within 5 days. As of August 2015, 24 states require patient notification 
of high breast density, an independent breast cancer risk factor which limits 
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mammography’s accuracy. Breast cancer screening also uses a standardized terminology, the 
Breast Imaging-Reporting and Data System, for findings and risk estimates. Although of 
unknown effect, no such laws or mandates exist for colorectal or cervical cancer screening, 
apart from minimum requirements for the National Breast and Cervical Cancer Early 
Detection Program. Some medical organizations recommend standardized formats, but their 
use and effectiveness are unknown.
 CONCLUSION
Cancer screening tests are commonly performed procedures, yet standards for their funding, 
quality metrics and reporting vary widely across organ types, without clear rationale. Breast 
cancer screening has many standards; some exist for cervical cancer, and few for colorectal 
cancer. These differences in screening standards may result, in part, from a system in which 
scientists, clinicians, legislators, and advocates focus on specific cancers rather than on 
common issues. Legislative approaches may improve standardization, but can create uneven 
care across organ types; non-evidence-based mandates may also enhance costs and burdens 
without improving outcomes or decreasing harms from screening.
Greater integration is needed to decrease cross-organ differences in cancer screening 
funding, quality, and reporting. The potential for a more comprehensive approach is 
reflected in NCI’s PROSPR initiative and with recent federal requirements for shared 
decision-making in lung cancer screening.7 PROSPR scientists identified several important 
questions for greater standardization across cancers, including:
• how to achieve consistent financial coverage of screening, follow-up testing, 
and treatment
• whom to screen
• when to screen
• appropriate follow-up intervals for abnormal results
• which quality metrics enhance outcomes
• how to provide uniform, clear and actionable result reporting
Consistent answers to these questions require specific, integrated cross-organ strategies and 
data to inform legislative changes and recommendations. We propose using patient-centered 
approaches and absolute incidence estimates of benefit, mortality, and harms across cancers. 
Such common metrics and goals may better unify the interests of patient advocacy, medical 
specialty, and payer groups; optimize effective screening practices; and diminish standards 
that are ineffective or even harmful. Using cross-organ metrics is a new approach, different 
from current legislative, USPSTF or guideline methods, which largely employ focused, 
serial, single-test and/or single-organ evaluations. An integrated approach can leverage new 
“big data” sources and innovative measurement approaches, such as in PROSPR, to compare 
screening processes and outcomes across organ types, and to develop more personalized 
strategies consistent with precision medicine. The next few years will be critical, given the 
rapidly changing landscape for current and new screening tests (e.g. computerized 
tomography for lung cancer and stool DNA testing). Cross-cutting data and dialogue across 
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the traditional organ-specific silos of research, clinical care, and advocacy are needed to 
achieve coherent, evidence-based, personalized, and effective standards of care for cancer 
screening.
This commentary is from centers that are part of the National Cancer Institute (NCI)-funded 
consortium Population-Based Research Optimizing Screening through Personalized 
Regimens (PROSPR). The overall aim of PROSPR is to conduct multi-site, coordinated, 
transdisciplinary research to evaluate and improve cancer screening processes. The ten 
PROSPR Research Centers reflect the diversity of U.S. delivery system organizations. 
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